Oppenheimer began coverage on shares of Climb Bio (NASDAQ:CLYM - Get Free Report) in a report issued on Friday,Briefing.com Automated Import reports. The firm set an "outperform" rating and a $10.00 price target on the stock.
Separately, BTIG Research initiated coverage on shares of Climb Bio in a research note on Thursday, May 22nd. They set a "buy" rating on the stock.
Read Our Latest Analysis on CLYM
Climb Bio Stock Performance
Shares of Climb Bio stock opened at $1.24 on Friday. The stock has a market cap of $83.79 million, a P/E ratio of -0.58 and a beta of -0.12. Climb Bio has a one year low of $1.05 and a one year high of $9.49. The stock's fifty day moving average price is $1.23.
Climb Bio (NASDAQ:CLYM - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.31) EPS for the quarter, missing analysts' consensus estimates of ($0.15) by ($0.16). As a group, equities analysts anticipate that Climb Bio will post -1.57 EPS for the current year.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently made changes to their positions in CLYM. RA Capital Management L.P. bought a new position in Climb Bio during the first quarter valued at approximately $38,332,000. Affinity Asset Advisors LLC acquired a new stake in Climb Bio during the first quarter worth $1,830,000. Peapod Lane Capital LLC acquired a new stake in shares of Climb Bio in the 1st quarter valued at $676,000. Allostery Investments LP acquired a new stake in shares of Climb Bio in the 1st quarter valued at $299,000. Finally, Persistent Asset Partners Ltd acquired a new position in Climb Bio during the 1st quarter worth about $178,000. 69.76% of the stock is currently owned by institutional investors and hedge funds.
Climb Bio Company Profile
(
Get Free Report)
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Climb Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Climb Bio wasn't on the list.
While Climb Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
